Differential response of BDCA-1+ and BDCA-3+ myeloid dendritic cells to respiratory syncytial virus infection

被引:18
|
作者
Gupta, Meera R. [1 ,2 ]
Kolli, Deepthi [2 ,3 ]
Garofalo, Roberto P. [2 ,3 ,4 ]
机构
[1] Univ Texas Med Branch, Dept Internal Med, Galveston, TX 77555 USA
[2] Univ Texas Med Branch, Dept Pediat, Galveston, TX 77555 USA
[3] Univ Texas Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA
[4] Univ Texas Med Branch, Sealy Ctr Mol Med, Galveston, TX 77555 USA
关键词
RSV; Myeloid dendritic cells; BDCA-1(+) mDCs; BDCA-3(+) mDCs; Primary DCs; Immune response; Costimulatory molecules; CD80; CD86; PD-L1; Cytokine profiles; CUTTING EDGE; GENERATION; EXPRESSION; ANTIGEN; IL-10; PHENOTYPE; CYTOKINES; INSIGHTS; SUBSETS; TRACT;
D O I
10.1186/1465-9921-14-71
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: Respiratory syncytial virus (RSV) is the leading cause of respiratory infections in children, elderly, and immunocompromised individuals. Severe infection is associated with short-and long-term morbidity including pneumonia, recurrent wheezing, and abnormal pulmonary function, and several lines of evidence indicate that impaired adaptive immune responses during infection are critical in the pathophysiology of RSV-mediated disease. Myeloid Dendritic cells (mDCs) play a pivotal role in shaping antiviral immune responses in the respiratory tract; however, few studies have examined the interactions between RSV and individual mDC subsets. In this study, we examined the effect of RSV on the functional response of primary mDC subsets (BDCA-1(+) and BDCA-3(+)) isolated from peripheral blood. Methods: BDCA-1(+) and BDCA-3(+) mDCs were isolated from the peripheral blood of healthy adults using FACS sorting. Donor-matched BDCA-1(+) and BDCA-3(+) mDCs were infected with RSV at a multiplicity of infection (MOI) of 5 for 40 hours. After infection, cells were analyzed for the expression of costimulatory molecules (CD86, CD80, and PD-L1), cytokine production, and the ability to stimulate allogenic CD4(+) T cell proliferation. Results: Both BDCA-1(+) and BDCA-3(+) mDCs were susceptible to infection with RSV and demonstrated enhanced expression of CD86, and the inhibitory costimulatory molecules CD80 and PD-L1. Compared to BDCA-3(+) mDCs, RSV-infected BDCA-1(+) mDC produced a profile of cytokines and chemokines predominantly associated with pro-inflammatory responses (IL-1 beta, IL-6, IL-12, MIP-1 alpha, and TNF-alpha), and both BDCA-1(+) and BDCA-3(+) mDCs were found to produce IL-10. Compared to uninfected mDCs, RSV-infected BDCA-1(+) and BDCA-3(+) mDCs demonstrated a reduced capacity to stimulate T cell proliferation. Conclusions: RSV infection induces a distinct pattern of costimulatory molecule expression and cytokine production by BDCA-1(+) and BDCA-3(+) mDCs, and impairs their ability to stimulate T cell proliferation. The differential expression of CD86 and pro-inflammatory cytokines by highly purified mDC subsets in response to RSV provides further evidence that BDCA-1(+) and BDCA-3(+) mDCs have distinct roles in coordinating the host immune response during RSV infection. Findings of differential expression of PD-L1 and IL-10 by infected mDCs, suggests possible mechanisms by which RSV is able to impair adaptive immune responses.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] Respiratory syncytial virus subverts the immune response through the induction of tolerogenic myeloid dendritic cells.
    Connolly, John
    Gill, Michelle
    Xue, Yaming
    Bhuta, Vikram
    Shay, Jennifer
    Banchereau, Jacques
    CLINICAL IMMUNOLOGY, 2006, 119 : S41 - S41
  • [22] Respiratory syncytial virus differentially activates murine myeloid and plasmacytoid dendritic cells
    Boogaard, Ivette
    van Oosten, Marijke
    van Rijt, Leonie S.
    Muskens, Femke
    Kimman, Tjeerd G.
    Lambrecht, Bart N.
    Buisman, Anne-Marie
    IMMUNOLOGY, 2007, 122 (01) : 65 - 72
  • [23] Respiratory syncytial virus infection and asthma link: Role of dendritic cells
    Nagy, SB
    Randall, TS
    Lockey, RF
    Mohapatra, SS
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2002, 109 (01) : S345 - S345
  • [24] Differential response of human naive and memory/effector T cells to dendritic cells infected by respiratory syncytial virus
    Rothoeft, T.
    Fischer, K.
    Zawatzki, S.
    Schulz, V.
    Schauer, U.
    Rettberg, C. Koerner
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2007, 150 (02): : 263 - 273
  • [25] γδ T cells and the immune response to respiratory syncytial virus infection
    McGill, Jodi L.
    Sacco, Randy E.
    VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, 2016, 181 : 24 - 29
  • [26] Central role of dendritic cells in shaping the adaptive immune response during respiratory syncytial virus infection
    McDermott, Daniel S.
    Weiss, Kayla A.
    Knudson, Cory J.
    Varga, Steven M.
    FUTURE VIROLOGY, 2011, 6 (08) : 963 - 973
  • [27] Contribution of Dendritic Cells in Protective Immunity against Respiratory Syncytial Virus Infection
    Jung, Hi Eun
    Kim, Tae Hoon
    Lee, Heung Kyu
    VIRUSES-BASEL, 2020, 12 (01):
  • [28] Multiple sclerosis: reduced proportion of circulating plasmacytoid dendritic cells expressing BDCA-2 and BDCA-4 and reduced production of IL-6 and IL-10 in response to herpes simplex virus type 1
    Sanna, A.
    Huang, Y. M.
    Arru, G.
    Fois, M. L.
    Link, H.
    Rosati, G.
    Sotgiu, S.
    MULTIPLE SCLEROSIS JOURNAL, 2008, 14 (09) : 1199 - 1207
  • [29] Role of IL-4Rα on myeloid dendritic cells in pathogenicity of respiratory syncytial virus infection and asthma development
    Shrestha, Bishwas
    You, Dahui
    Saravia, Jordy
    Siefker, David
    Cormier, Stephania
    JOURNAL OF IMMUNOLOGY, 2015, 194
  • [30] PHASE I CLINICAL TRIAL ON INTRATUMORAL ADMINISTRATION OF AUTOLOGOUS CD1C (BDCA-1)+/ CD141 (BDCA-3)+ MYELOID DENDRITIC CELLS PLUS IPILIMUMAB AND AS01B IN COMBINATION WITH INTRAVENOUSLY ADMINISTERED NIVOLUMAB
    Tijtgat, Jens
    Schwarze, Julia Katharina
    Vander Mijnsbrugge, An-Sofie
    Raeymaeckers, Steven
    Van Riet, Ivan
    Geeraerts, Xenia
    Stevens, Latoya
    Tuyaerts, Sandra
    Neyns, Bart
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A823 - A823